Temozolomide

Catalog No.S1237 Synonyms: CCRG81045, NSC 362856

Temozolomide Chemical Structure

Molecular Weight(MW): 194.15

Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 170 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Talazoparib and temozolomide exhibit marked combinatorial efficacy in PDXs. A, Western blot against MGMT by near-infrared imaging in PDX models.

    Clin Cancer Res, 2017, 23(2):523-535. Temozolomide purchased from Selleck.

    C57BL/6 mice were implanted in the striatum with citrine-GL26-Cherry-HMGB1, which were stably transfected to express the YFP citrine and HMGB1 fused to red fluorescent protein cherry. Fourteen days later, they were treated with saline, Ad-TK+Ad-Flt3L, or Ad-TK+Ad-Flt3L+TMZ (temozolomide). Five days after treatment, the cellular location of cherry-HMGB1 in these cells was assessed by confocal microscopy. Arrows, tumor cells (green) with cytoplasmic HMGB1 (red).

    Clin Cancer Res 2014 20(6), 1555-65. Temozolomide purchased from Selleck.

  • Viability of U87 cells(A) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs temozolomide (TMZ) and Bliss interaction index (B) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 400 μM TMZ(A) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-18.. Temozolomide purchased from Selleck.

    Cells were plated and 12 h after plating were treated with MMF (5 µM), FTY720 (50 nM), Temozolomide (TMZ, 3 µM) or in combination as indicated for 12 h. Cell viability was assessed by live / dead assay.

    Cancer Biol Ther, 2014, 15(12):1646-57. Temozolomide purchased from Selleck.

  • Establishment of TMZ-resistant (TR) GBM cell lines. a-d, Evaluation of temozolomide resistance in four glioblastoma cell lines. Cells were cultured in the presence of 5-600 μM of TMZ. A dose-dependent association between the survival rate of cells and TMZ concentration can be observed. Each group was cultured for 24 h in the presence of different concentrations of TMZ, followed by an evaluation of IC50 for TMZ inhibited growth in A172-TR/A172, U118-TR/U118, U251-TR/U251 and U87-TR/U87

    Neurochem Res, 2016, 41(12):3192-3205. Temozolomide purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.
Features Methazolastone is a second-generation alkylating agent.
Targets
DNA replication [1]
(L-1210, L-1210/BCNU cells)
In vitro

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. [2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. [3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. [4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly M4[wR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnWbHU1QCCq NV32RmtTUUN3ME2xN|kvOjEkgJpCtgKBkTVwOUWg{txO Moi3NlU6PjB{OEK=
KellyCis83 NXzjfWdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrIXGlXPDhiaB?= NGr6XGRKSzVyPUK1NU4xOOLCidMx5qCKOTVwN{Wg{txO MWCyOVk3ODJ6Mh?=
SK-N-AS NYfjeI9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLsWXVXPDhiaB?= NWDwOHNJUUN3ME2yNlcvPzEkgJpCtgKBkTJ{LkG1JO69VQ>? NYr4PYhoOjV7NkCyPFI>
SK-N-ASCis24 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnSzOFghcA>? MWfJR|UxRTR6MD62NQKBkcLz4pEJNVAyNjF3IN88US=> M3LROlI2QTZyMkiy
CHP-212 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjPfYk1QCCq NHXOPZVKSzVyPUeuPVfjiIoEsfMAjVAvPjlizszN NEXXd4ozPTl4MEK4Ni=>
CHP-212Cis100 NHvMT3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfTOmg1QCCq NX7tUldxUUN3ME25MlU26oDLwsJihKkxNjh6IN88US=> MWGyOVk3ODJ6Mh?=
U87  NGHDO5ZHfW6ldHnvckBCe3OjeR?= M4XZe|ExOCEQvF2= MojuNlQuPzJiaB?= M1vBSolv\HWlZYOgSINTOSCneIDy[ZN{cW:w NGPhRVYzPThyOEi2PC=>
LN229 Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVqwMVUxKM7:TR?= NUiwfVNuUUN3ME2xOkDPxE1? MWKyOVc2ODJ5Mx?=
TR-LN229 NYjMSmVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLh[m0xNTVyIN88US=> M2LISWlEPTB;N{eg{txO NV34R4VNOjV5NUCyO|M>
U87  M2DRU2Fxd3C2b4Ppd{BCe3OjeR?= MnrENQKBmzJyMPMAjeK2VQ>? NYLUXmhoOjRiaB?= MoTt[Y5p[W6lZYOgR3EhcW6mdXPl[EBieG:ydH;zbZM> MWmyOVY5OTZ4OB?=
U251MG MWrBdI9xfG:|aYOgRZN{[Xl? NULIfplKOTBywrFOwG0> M3[zUFQ5KGh? MlPZVGJU MVvpcoR2[2W|IHHwc5B1d3Orcx?= MlXMNlU3QDB2NkS=
U87MG NXXIbHJsSXCxcITvd4l{KEG|c3H5 NXyzb5VmOTBywrFOwG0> MYm0PEBp NH3WcWFRSlN? NFnrSoNqdmS3Y3XzJIFxd3C2b4Ppdy=> MWWyOVY5ODR4NB?=
U87 NH3HTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPHOVAuOzVyIN88US=> M1v0TVQ5yqCqwrC= M1LxNYlvcGmkaYTzJINmdGxiZ4Lve5RpKHOuaXfoeIx6 MVKyOVU2PDJ{Mx?=
U118  NEjxSlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrNOVAuOzVyIN88US=> MXe0POKhcMLi MorsbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2yrZ3j0cJk> NHfTZXQzPTV3NEKyNy=>
U87 MV;GeY5kfGmxbjDBd5NigQ>? MU[yOVAwOzVyIN88US=> M{DVflQ5yqCqwrC= MX\lcohidmOnczDUUXgucW6mdXPl[EBxNVCNQz3wZY4h\GWlcnXhd4U> NF;mbIszPTV3NEKyNy=>
U118  M{\aTWZ2dmO2aX;uJGF{e2G7 NFHySVEzPTBxM{WwJO69VQ>? MVG0POKhcMLi NH\kRnVmdmijbnPld{BVVVhvaX7keYNm\CCyLWDLR{1x[W5iZHXjdoVie2V? M1;4O|I2PTV2MkKz
U87 MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHz4e3QzPTBxM{WwJO69VQ>? MX[0POKhcMLi NIn0d49qdmO{ZXHz[ZMhfGinIIDldoNmdnSjZ3Wgc4Yh[2WubIOgbY4hWyCjbnSgS|IwVcLiY3;0doVifGWmIIfpeIghXE2[ MYiyOVU2PDJ{Mx?=
A375 M3rxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzlelk1QMLiaNMg MmfiTWM2OD1{NkWg{txO MnPKNlU2OjR3NUK=
A2058 NELkPHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK4WFVpPDkEoHlCpC=> MUjJR|UxRTF{IN88US=> MnTqNlU2OjR3NUK=
M238 NG\RVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYi0POKhcMLi NHvDZnVKSzVyPUSwJO69VQ>? NFHuXWEzPTV{NEW1Ni=>
M249 MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY[0POKhcMLi M2noRmlEPTB;MkW0JO69VQ>? Mm[0NlU2OjR3NUK=
M21 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXj4RWloPDkEoHlCpC=> MXXJR|UxRTJ{MTFOwG0> NFfqU4IzPTV{NEW1Ni=>
U251 MlewR5l1d3SxeHn0fUBCe3OjeR?= MVWyNEDPxE4EoB?= NHvzcWs1QMLiaNMg NIXNPY9z\WS3Y3Xkd{B1cGVicHXyZ4VvfGGpZYOgc4Yh[2:ub37p[ZMh\m:{bXXk MX:yOVQ{PDN6MR?=
LN229 Mle3R5l1d3SxeHn0fUBCe3OjeR?= M3nocFIxKM7:TdMg NVez[XJLPDkEoHlCpC=> NUXiW2NyemWmdXPl[JMhfGinIIDldoNmdnSjZ3XzJI9nKGOxbH;ubYV{KG[xcn3l[C=> NH7ycm4zPTR|NEO4NS=>
U373MG-LUC MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[3NkBp NHLiVnJKSzVyPk[wNEDPxE1? MYWyOVQ{OTl3Mx?=
U87  M1jSU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYiyOU0zODBizszN NIS0VY81QMLiaNMg MnTjbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NIPrUYMzPTRyMEe0OS=>
U251 M1\vd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEex[nczPS1{MECg{txO MYC0POKhcMLi NYDGNoc{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2r1clI2PDByN{S1
U251 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkG4NVAxNTRyMDFOwG0> NXrnVWhoPzJxOU[gbC=> MUL0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:|c4nwc4wh\W6qYX7j[YQhyqB? NYLjV3g5OjV|N{WyO|E>
U373 NWPJT2dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHSVFIyODBvNECwJO69VQ>? NFHlZ3g4Oi97NjDo NI[2TYd1cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC= MmPPNlU{PzV{N{G=
U343 M3;NT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DRUFExOC12MECg{txO NX\pXIs5PzJxOU[gbC=> NVzycXRTfGinIHHueIkueHKxbHnm[ZJifGm4ZTDl[oZm[3RiY3HuJIJmKGWwaHHuZ4VlKGK7IHfvd5N6eG:uIHXubIFv[2WmINMg NHLrWFYzPTN5NUK3NS=>
U87MG-luc2 NUTNb4pKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[xNFAuPDByIN88US=> M1y5RVczNzl4IHi= Mn3OeIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi NHTySHUzPTN5NUK3NS=>
U87 NGe3O5ZHfW6ldHnvckBCe3OjeR?= MkD4NlAxKM7:TR?= M{DXZ|Q5KGh? MkPwbY5kemWjc3XzJGJTS0N|IH3SUmEh\XiycnXzd4lwdg>? NG\WbnkzPTN|N{eyNS=>
U251 MVLGeY5kfGmxbjDBd5NigQ>? MlPUNlAxKM7:TR?= Mnf6OFghcA>? M{PYRYlv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25? NG\wUmYzPTN|N{eyNS=>
A172 NYPPNWJ5TnWwY4Tpc44hSXO|YYm= NXLFZlFxOjByIN88US=> NILtdI01QCCq M{\kOYlv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25? MVSyOVM{Pzd{MR?=
U251 NUjnNXdFTnWwY4Tpc44hSXO|YYm= MkWwNlAxKM7:TR?= NFfy[5M1QCCq Mn;2bY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGJTS0FzLDDCVmNCOixiUlHEOVEh[W6mIF\BUmNFOg>? NHniNFgzPTN|N{eyNS=>
A172 MVfGeY5kfGmxbjDBd5NigQ>? NGfheo4zODBizszN MV20PEBp NHfQW41qdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhSlKFQUGsJGJTS0F{LDDSRWQ2OSCjbnSgSmFPS0R{ NFPvU5MzPTN|N{eyNS=>
U87 NFLZS2VHfW6ldHnvckBCe3OjeR?= NWPPWXFpOjByIN88US=> Mlf1NlQwPzJxMUKwJIg> NX\NWppmcW6lcnXhd4V{KM7|SELBXEBnd2OrIH\vdo1ifGmxbjD0bY1mNWSncHXu[IVvfGy7 MUOyOVM{Pzd{MR?=
U251 MXTGeY5kfGmxbjDBd5NigQ>? NUfidpY1OjByIN88US=> NV3HR5dROjRxN{KvNVIxKGh? MnfpbY5kemWjc3XzJO6{UDKDWDDmc4NqKG[xcn3heIlwdiC2aX3lMYRmeGWwZHXueIx6 Mnv5NlU{Ozd5MkG=
A172 NVXGOZNqTnWwY4Tpc44hSXO|YYm= MYmyNFAh|ryP M{DObFI1Nzd{L{GyNEBp MVrpcoNz\WG|ZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9vKHSrbXWt[IVx\W6mZX70cJk> MW[yOVM{Pzd{MR?=
SNB19V MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWq3JIQ> M3:wc2ROW09? NX;K[WRFT0l3ME2zOU44yrFzMjFOwG0> MlvrNlUzPzd2NEG=
SNB19M NX3DRphsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfzU3M{PyCm NYf6SJVETE2VTx?= M{TTfGdKPTB;NE[5MlnDuTh6IN88US=> Mlr2NlUzPzd2NEG=
SNB19VR NVHiSotQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nwSFch\A>? MkX2SG1UVw>? NWfzcZlZT0l3ME2yPFAvOsLzMUig{txO NH;XSVEzPTJ5N{S0NS=>
U373V NHPJNW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LWNVch\A>? NYrDR4ZJTE2VTx?= M{faV2dKPTB;NkiuNOKyOzJizszN NVjtRmtuOjV{N{e0OFE>
U373M M4ntUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j2TFch\A>? MkfGSG1UVw>? M1PpSmdKPTB;M{[4MlfDuTh4IN88US=> MnLNNlUzPzd2NEG=
U373VR MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr4dpE4KGR? NILDeXFFVVOR M{TISmdKPTB;Mki4MljDuTN|IN88US=> M2WzblI2Ojd5NESx
U87MG NXrqU3VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHkTG04KGR? MlLzSG1UVw>? NYX0bGRHT0l3ME2zPE4{yrF{MDFOwG0> M1zQUlI2Ojd5NESx
HCT116 NV7teXRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWW3JIQ> NGe0cVNFVVOR NY\tNoZET0l3ME21O|kvQcLzM{Kg{txO MWCyOVI4PzR2MR?=
DLD1 M1XKTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XKRVch\A>? Mn\ZSG1UVw>? M2DFcmdKPTB;NUCxMlTDuTl|IN88US=> Mk\jNlUzPzd2NEG=
MRC5 MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID4V3A4KGR? MofGSG1UVw>? MlLzS2k2OD12NEmuOOKyQCEQvF2= M3LRclI2Ojd5NESx
SNB19V  MlTDSpVv[3Srb36gRZN{[Xl? MlXKNVAxKM7:TdMgWG1b M4nMSVAuPzJiaB?= MVvpcoNz\WG|ZYOg{tNJOkG[IHX4dJJme3Orb36gZoV1f2WnbjCxOkBidmRiN{KgbC=> M2HG[lI2Ojd5NESx
T98G  NX;rSHRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWq1M|ExNzF3IN88US=> MYSyOOKhcA>? NEfLeYhqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZT3k[ZBmdmSnboTsfUBi\nSncjDjc45kd22rdHHueE11\W2xen;sc41q\GVid3n0bEBPWGV4LWDEWC=> M13xZVI2OjZ{OU[x
U251  MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTWeWNtPS9zMD:xOUDPxE1? M1;GcFI1yqCq NHv1c2pqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZT3k[ZBmdmSnboTsfUBi\nSncjDjc45kd22rdHHueE11\W2xen;sc41q\GVid3n0bEBPWGV4LWDEWC=> MXyyOVI3Ojl4MR?=
T98G  NEHsN5FHfW6ldHnvckBCe3OjeR?= MYKxOUDPxE1? NXrxdnI{OjUEoHi= MoDSbY5kemWjc3XzJGRPSS2ocnHncYVvfGG2aX;uJIlvKE6SZU[tVGRVKHS{ZXH0[YQh\2yrb33hJINmdGy| NXLwd2NQOjV{NkK5OlE>
U251  NWPmc5B6TnWwY4Tpc44hSXO|YYm= NVHNTGNiOTVizszN MmP6NlTDqGh? NEPOTHRqdmO{ZXHz[ZMhTE6DLX\yZYdu\W62YYTpc44hcW5iTmDlOk1RTFRidILlZZRm\CCpbHnvcYEh[2WubIO= NYHnTphSOjV{NkK5OlE>
U-87 MG MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjoZ2U4OiCq M1rBNWlEPTB;MD65N{BuVcLi MoTqNlUzPDV|M{K=
U-118 MG NW\1Z3lZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml6wO|IhcA>? MVTJR|UxRTFwMEWgcW3DqA>? M3;iRVI2OjR3M{Oy
U87 NV:xTFNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjZ[lQzPCCq M1LUfmlEPTB;Mk[wMlM1KM7:TdMg MXSyOVE4OzJ|Mx?=
U87 GSLCs NIXwNVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV6yOEBp M4jBR2lEPTB;N{[2MlEyKM7:TdMg MkjBNlUyPzN{M{O=
U87MG NYm4[29ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXO3NkBp M4LYd2lEPTB;MUWuOlI2KM7:TdMg NEDXfmszPTB3MEmxOS=>
U251 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTzb4EyODBvNECwJO69VQ>? MXm0PEBp MnLQSG1UVw>? NXvQNmV6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXnFNGJYOjR4MkO3N|Y>
U87 NVXNdoE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{T2PFExOC12MECg{txO NHjhSJM1QCCq MYXEUXNQ NEf2dZpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MkXpNlQ3OjN5M{[=
MDA-MB-231-br NWSzUXpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjHdmoxNTFyIN88US=> Mkf2OFghcA>? NVT2dpRSTE2VTx?= NX7ud5ozcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NH\HXWozPDZ{M{ezOi=>
HCC-1937 M4DLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7kbXptOC1|MECg{txO NID6Nmo1QCCq MXzEUXNQ NXi3W|d1cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MUiyOFYzOzd|Nh?=
MDA-MB-231 NWTzd5dST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17JcVAuPDBizszN MUO0PEBp NIXqc2NFVVOR NYLSZZNFcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2XNZVI1PjJ|N{O2
MDA-MB-468 NUTsSFZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXPNE02ODBizszN M1X3blQ5KGh? NInrS3BFVVOR MUDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NULSfZhTOjR4MkO3N|Y>
T47D MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPjWVJpOC1zMECg{txO M4i3WlQ5KGh? NFOwOZBFVVOR M3HxNIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M2W1S|I1PjJ|N{O2
MCF7 NVPrNFFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYmwMVExODBizszN NELOOYQ1QCCq NUftb5ZlTE2VTx?= NXm5b4J2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MkHrNlQ3OjN5M{[=
Hs683 MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUKwMVExODBizszN MYm5OkBp MYXJR|UxRTF{OD65JO69VQ>? NIizV4YzPDR7NUmwOy=>
U87 NXXoTWl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PF[VAuOTByMDFOwG0> M2\IRlk3KGh? MXPJR|UxRTF6LkS1JO69VQ>? MVKyOFQ6PTlyNx?=
LNZ308 MnrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVWwMVExODBizszN M3HXW|k3KGh? M4H2cWlEPTB;M{K2Mlch|ryP NVi3PIpjOjR2OUW5NFc>
U87 Mnj1RZBweHSxc3nzJGF{e2G7 MUWxNFAh|ryP M3P5dlQ5KGh? MUnEUXNQ MX;pcoNz\WG|ZYOgeIhmKGOjc4Dhd4UuOy95IHHjeIl3cXS7 NVnjXmZTOjR2OEG1PFY>
U251  NELTU4lCeG:ydH;zbZMhSXO|YYm= NI\F[2syODBizszN M{GwblQ5KGh? NHOzb2JFVVOR NHvqPWdqdmO{ZXHz[ZMhfGinIHPhd5Bie2VvMz:3JIFkfGm4aYT5 M3rrVVI1PDhzNUi2
U251 NFrv[nNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[4N4ZZOjRiaB?= M1LKTmlEPTB;OE[uNlnjiIoEsfMAjVEvPThizszN MnvDNlQ{OjZ7NUS=
U251 NUfv[3BTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HEZVQ5KGh? NHm1eHZKSzVyPUe1MlM16oDLwsJihKkyNjB{IN88US=> Mn\DNlQ{OjZ7NUS=
U251 Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVK3NkBp NX;INFdkUUN3ME23Nk41OuLCidMx5qCKOS52NTFOwG0> M{PBW|I1OzJ4OUW0
U251 M2[wUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLQZ4tWQTZiaB?= MoTkTWM2OD14OT64NwKBkcLz4pEJN{4xPCEQvF2= M4PsW|I1OzJ4OUW0
T98G M3vDU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTMNE04PTBizszN NHvuN|M4Oi97NjDo NF7TfmRqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MYmyOFMzPDB6MB?=
U251-MG M2fVO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MViwMVgxOCEQvF2= M4DzUVczKGh? NELsV4hqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MVmyOFA6OzZ|MB?=
D54-MG NHHVZ2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHaO2ZoOC16MECg{txO MmGxO|IhcA>? MY\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M1vTTlI1ODl|NkOw
SHG-44 NETO[FBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXqxNE0zODBizszN NWmxdWYyQTZiaB?= MlTZTWM2OD17LkezJOKyKDJwMUKg{txO NFv0dG8zPDB4NUW2PS=>
U373  M4jCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUixNE0zODBizszN NF[1e2M6PiCq M3Loe2lEPTB;MUCuNVMhyrFiMT6wNkDPxE1? NVPXSotuOjRyNkW1Olk>
HT-29  NIXY[W5HfW6ldHnvckBCe3OjeR?= NGSzWG42ODBizszN MV:yOE81QCCq MmKw[Y5p[W6lZYOgeIhmKGyndnXsd{Bw\iEQsz3INmFZyqB? NGTS[pgzPDB|OEC2PC=>
PC-3  NWPDTG9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGwMVI2KM7:TR?= NHXZVoo1QCCq MV\pcohq[mm2czDj[YxtKGe{b4f0bEB4cGmlaDDjZY4h[mVicH;0[Y51cWG2ZXSgZpkhdHmlb4DlcoU> NELaUZYzOzd2NkmzOC=>
PC-3  MWDBdI9xfG:|aYOgRZN{[Xl? MVyyOUDPxE1? MWK0PEBp NWr6[oVrcW6mdXPld{BieG:ydH;zbZMhf2irY3igZ4FvKGKnIIDveIVvfGmjdHXkJIJ6KGy7Y3;w[Y5m NUPvdJBDOjN5NE[5N|Q>
T98G MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjwOVAuPDByIN88US=> M{nCdlE1PCCq MX7pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NYPYXoxXOjN5MUW0PVk>
U87-MG MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTRbYxxOTByINM1US=> Mlq2O|IhcA>? MkjhbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIHXubIFv[2WmIHL5JGdVSg>? M2DXN|I{Pjl4N{i4
U251-MG NY\kW3pwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH6O5NUOTByINM1US=> NVe2XHhyPzJiaB?= M3S0PYlvcGmkaYTzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDlcohidmOnZDDifUBIXEJ? NELWOIYzOzZ7Nke4PC=>
LNT-229 NHzjR5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXofHo{NTFyMDFOwG0> MX[yOEBp M1u0fIlvcGmkaYTzJINtd26xZ3XubYMhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M{fJc|I{PjZ5NkOy
T98G M37QUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfKNVAuPzByIN88US=> MV6yOEBp M2O4NYlvcGmkaYTzJINtd26xZ3XubYMhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NWDxRXFTOjN4Nke2N|I>
U87  NITBOIFHfW6ldHnvckBCe3OjeR?= M4XpUlExOCEEtV2= MkHzN{Bp MX\lcIV3[XSnczD0bIUhdGW4ZXzzJI9nKHCFaHuxJIFv\CCyQ3jrNi=> MlK3NlM3Pjd2Nkm=
HCT116 MXnGeY5kfGmxbjDBd5NigQ>? MUOxNFAhyrWP Mn7uN{Bp NWfIZ3NzcW6mdXPld{B1cGViQ3jrNUBRcG:|cHjvdplt[XSrb36= M13rUlI{PjZ5NE[5
HCT3-6 NW\RepdYTnWwY4Tpc44hSXO|YYm= M4HLeFExOCEEtV2= MVWzJIg> MV\pcoR2[2W|IITo[UBEcGtzIGDoc5NxcG:{eXzheIlwdg>? Mlr1NlM3Pjd2Nkm=
U-87  MmDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;VOVlNOC12MDFOwG0> NUnjRndyOTJiZB?= NVvpcmZOcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVm1eYtLOjN4NEW3Nlk>
U-87  NYXXcJNRSXCxcITvd4l{KEG|c3H5 NHvz[m8xNTRyIN88US=> NVfTOHVZOy94IHS= NVLPbFQxcW6mdXPld{BieG:ydH;zbZMhcW5iYn;0bEBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MXeyN|Y1PTd{OR?=
U-87  NWT0e2ptTnWwY4Tpc44hSXO|YYm= NWnjWnlzOC12MDFOwG0> M{XC[FMwPiCm NFvwdoVqdmS3Y3XzJIF2fG:yaHHnfUBqdiCkb4ToJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? M1\lflI{PjR3N{K5
GB-SCC010 NYHrcG9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn0cmszPCCm MlXCTWM2OD1{Mk[g{txO M3jkdlI{PjF{N{W1
GB-SCC026 NF6wUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXCPZV4PCCm MmPrTWM2OD13Mz6xJO69VQ>? NYrMZ4dzOjN4MUK3OVU>
GB-SCC028 M161Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fxVVQh\A>? NVfBfVh4UUN3ME2xOlch|ryP MmjKNlM3OTJ5NUW=
U87 NFTF[|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYSyS|c6PCCm M2SycWlEPTB;NEWuNkDPxE1? NFvlUXAzOzZzMke1OS=>
U87 stem cell MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moi5OEBl M{\zO2lEPTB;Nk[uO{DPxE1? NWLVUmROOjN4MUK3OVU>

... Click to View More Cell Line Experimental Data

In vivo After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. [1]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: L-1210 and L-1210/BCNU cells
  • Concentrations: 0 μM -100 μM
  • Incubation Time: l hours
  • Method:

    L-1210 and L-1210/BCNU cells are seeded at 0.2 × 104 cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 105 and 8 × 105/mL. Control growth is logarithmic in this range.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: DBA/2 mice with L-1210 and L-1210/BCNU cells
  • Formulation: 95% ethanol
  • Dosages: 40 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 194.15
Formula

C6H6N6O2

CAS No. 85622-93-1
Storage powder
Synonyms CCRG81045, NSC 362856

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02977780 Recruiting Glioblastoma Dana-Farber Cancer Institute|Eli Lilly and Company|Celgene|Puma Biotechnology, Inc.|Accelerate Brain Cancer Cure February 9, 2017 Phase 2
NCT02689336 Recruiting Glioma|Rhabdomyosarcoma|Osteosarcoma|Medulloblastoma|Neuroectodermal Tumor|Ependymoma|Ewings Sarcoma|Wilms Tumor Washington University School of Medicine August 6, 2016 Phase 2
NCT02455557 Recruiting Glioblastoma|Gliosarcoma Roswell Park Cancer Institute|National Cancer Institute (NCI) May 5, 2015 Phase 2
NCT01473901 Active, not recruiting Glioblastoma Novartis Pharmaceuticals|Novartis December 30, 2011 Phase 1
NCT03018288 Not yet recruiting Glioblastoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 3, 2017 Phase 2
NCT02766270 Recruiting Grade II/III Glioma Beijing Tiantan Hospital|Beijing Neurosurgical Institute|Beijing Shijitan Hospital September 26, 2016 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Temozolomide | Temozolomide ic50 | Temozolomide price | Temozolomide cost | Temozolomide solubility dmso | Temozolomide purchase | Temozolomide manufacturer | Temozolomide research buy | Temozolomide order | Temozolomide mouse | Temozolomide chemical structure | Temozolomide mw | Temozolomide molecular weight | Temozolomide datasheet | Temozolomide supplier | Temozolomide in vitro | Temozolomide cell line | Temozolomide concentration | Temozolomide nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID